Strs Ohio Takes $2.05 Million Position in Moderna, Inc. $MRNA

Key Points

• Strs Ohio has made a new investment of $2.05 million in Moderna, acquiring 72,280 shares of the company.
• Moderna's stock has a market cap of $9.29 billion and its earnings report showed a loss of ($2.13)** per share, beating analyst expectations.
• Analysts have mixed views on Moderna, with an average rating of "Hold" and a consensus price target of $41.81.

Strs Ohio bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 72,280 shares of the company's stock, valued at approximately $2,049,000.

A number of other hedge funds have also made changes to their positions in MRNA. Voloridge Investment Management LLC raised its holdings in shares of Moderna by 335.6% during the fourth quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock valued at $107,727,000 after acquiring an additional 1,996,003 shares during the last quarter. SHANDA ASSET MANAGEMENT HOLDINGS Ltd acquired a new position in shares of Moderna during the first quarter valued at approximately $28,350,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Moderna in the first quarter valued at approximately $28,308,000. Jump Financial LLC increased its holdings in shares of Moderna by 5,590.0% in the first quarter. Jump Financial LLC now owns 902,427 shares of the company's stock valued at $25,584,000 after purchasing an additional 886,567 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Moderna by 17.5% in the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock valued at $166,801,000 after purchasing an additional 877,162 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on MRNA. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. Barclays cut their price target on Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a report on Monday, August 4th. Bank of America cut their price target on Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a report on Tuesday, July 22nd. Leerink Partners lowered their price objective on Moderna from $18.00 to $15.00 and set an "underperform" rating for the company in a research report on Friday, August 22nd. Finally, Evercore ISI set a $32.00 price objective on Moderna in a research report on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, fourteen have given a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $41.81.

Moderna Stock Performance

NASDAQ MRNA traded down $0.43 during trading on Friday, reaching $25.02. 8,147,398 shares of the company's stock were exchanged, compared to its average volume of 10,890,682. The stock has a market cap of $9.73 billion, a P/E ratio of -3.33 and a beta of 1.93. The company has a 50 day moving average price of $27.73 and a two-hundred day moving average price of $28.03. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $67.96.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.Moderna's revenue for the quarter was down 41.1% on a year-over-year basis. During the same period in the previous year, the business earned ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. Research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.